MedTrace Logo

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

NCT00352742 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2008-10-28

No results posted yet for this study

Summary

The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.

Conditions

Interventions

DRUG

ATN-224 + bortezomib

ATN-224 and bortezomib dose to be determined in Phase I portion of study

Sponsors & Collaborators

  • Attenuon

    lead INDUSTRY

Principal Investigators

  • Gilad Gordon, MD

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-09-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352742 on ClinicalTrials.gov